Skip to main content
SpringerLink
Log in

Management of Side Effects in the Personalized Medicine Era: Chemotherapy-Induced Peripheral Neuropathy

  • Protocol
  • First Online:
Pharmacogenomics in Drug Discovery and Development

Part of the book series: Methods in Molecular Biology ((MIMB,volume 1175))

Abstract

Pharmacogenomics has been establishing itself as a powerful tool to predict individual response to treatment, in order to personalize therapy management; this field has been explored in particular in Oncology. Not only efficacy on the malignant disease has been investigated, but also the possibility to predict adverse effects due to drug administration. Chemotherapy-Induced Neurotoxicity (CIPN) is one of those. This potentially severe and long-lasting/permanent side effect of commonly administered anticancer drugs can severely impair Quality of Life (QoL) in a large cohort of long survival patients. So far, a pharmacogenomics-based approach in CIPN regard has been quite delusive, making a methodological improvement warranted in this field of interest: even the most refined genetic analysis cannot be effective if not applied correctly. Here, we try to devise why it is so, suggesting how THE “bench-side” (Pharmacogenomics) might benefit from and should cooperate with THE “bed-side” (Clinimetrics), in order to make genetic profiling effective if applied to CIPN.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Protocol
USD 49.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  1. Syvanen AC (2005) Toward genome-wide SNP genotyping. Nat Genet 37(Suppl):S5–S10

    Article  PubMed  Google Scholar 

  2. Argyriou AA, Bruna J, Marmiroli P, Cavaletti G (2012) Chemotherapy-induced peripheral neurotoxicity (CIPN): an update. Crit Rev Oncol Hematol 82:51–77

    Article  PubMed  Google Scholar 

  3. Cavaletti G, Frigeni B, Lanzani F et al (2010) Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer 46:479–494

    Article  CAS  PubMed  Google Scholar 

  4. Ekhart C, Rodenhuis S, Smits PH, Beijnen JH, Huitema AD (2009) An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment. Cancer Treat Rev 35:18–31

    Article  CAS  PubMed  Google Scholar 

  5. Strange RC, Spiteri MA, Ramachandran S, Fryer AA (2001) Glutathione-S-transferase family of enzymes. Mutat Res 482:21–26

    Article  CAS  PubMed  Google Scholar 

  6. Funke S, Timofeeva M, Risch A et al (2010) Genetic polymorphisms in GST genes and survival of colorectal cancer patients treated with chemotherapy. Pharmacogenomics 11:33–41

    Article  CAS  PubMed  Google Scholar 

  7. Stoehlmacher J, Park DJ, Zhang W et al (2002) Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 94:936–942

    Article  CAS  PubMed  Google Scholar 

  8. Zarate R, Rodriguez J, Bandres E et al (2010) Oxaliplatin, irinotecan and capecitabine as first-line therapy in metastatic colorectal cancer (mCRC): a dose-finding study and pharmacogenomic analysis. Br J Cancer 102:987–994

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  9. Martin LP, Hamilton TC, Schilder RJ (2008) Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 14:1291–1295

    Article  CAS  PubMed  Google Scholar 

  10. Segurel L, Lafosse S, Heyer E, Vitalis R (2010) Frequency of the AGT Pro11Leu polymorphism in humans: does diet matter? Ann Hum Genet 74:57–64

    Article  CAS  PubMed  Google Scholar 

  11. Levi F, Perpoint B, Garufi C et al (1993) Oxaliplatin activity against metastatic colorectal cancer: a phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer 29A:1280–1284

    Article  CAS  PubMed  Google Scholar 

  12. Crowley E, Callaghan R (2010) Multidrug efflux pumps: drug binding – gates or cavity? FEBS J 277:530–539

    Article  CAS  PubMed  Google Scholar 

  13. Sharom FJ (2008) ABC multidrug transporters: structure, function and role in chemoresistance. Pharmacogenomics 9:105–127

    Article  CAS  PubMed  Google Scholar 

  14. Henningsson A, Marsh S, Loos WJ et al (2005) Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res 11: 8097–8104

    Article  CAS  PubMed  Google Scholar 

  15. Zhou SF, Liu JP, Chowbay B (2009) Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 41:89–295

    Article  CAS  PubMed  Google Scholar 

  16. Mielke S, Sparreboom A, Steinberg SM et al (2005) Association of paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res 11:4843–4850

    Article  CAS  PubMed  Google Scholar 

  17. Scuteri A, Galimberti A, Maggioni D et al (2009) Role of MAPKs in platinum-induced neuronal apoptosis. Neurotoxicology 30:312–319

    Article  CAS  PubMed  Google Scholar 

  18. Durand JP, Deplanque G, Montheil V et al (2009) Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial. Ann Oncol 20:736–740

    Article  PubMed  Google Scholar 

  19. Argyriou AA, Chroni E, Koutras A et al (2006) Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of vitamin E supplementation. J Pain Symptom Manage 32:237–244

    Article  CAS  PubMed  Google Scholar 

  20. Argyriou AA, Chroni E, Koutras A et al (2006) A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results. Support Care Cancer 14:1134–1140

    Article  PubMed  Google Scholar 

  21. Pace A, Giannarelli D, Galie E et al (2010) Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial. Neurology 74:762–766

    Article  CAS  PubMed  Google Scholar 

  22. Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot MA (2006) Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 12:3050–3056

    Article  CAS  PubMed  Google Scholar 

  23. Ruzzo A, Graziano F, Loupakis F et al (2007) Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy. J Clin Oncol 25:1247–1254

    Article  CAS  PubMed  Google Scholar 

  24. Oldenburg J, Kraggerud SM, Brydoy M et al. (2007) Association between long-term neuro-toxicities in testicular cancer survivors and polymorphisms in glutathione-s-transferase-P1 and -M1, a retrospective cross sectional study. J Transl Med 5:70

    Google Scholar 

  25. Goekkurt E, Al-Batran SE, Hartmann JT et al (2009) Pharmacogenetic analyses of a phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil and leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie. J Clin Oncol 27:2863–2873

    Article  CAS  PubMed  Google Scholar 

  26. Hong J, Han SW, Ham HS et al (2011) Phase II study of biweekly S-1 and oxaliplatin combination chemotherapy in metastatic colorectal cancer and pharmacogenetic analysis. Cancer Chemother Pharmacol 67:1323–1331

    Article  CAS  PubMed  Google Scholar 

  27. Li QF, Yao RY, Liu KW et al (2010) Genetic polymorphism of GSTP1: prediction of clinical outcome to oxaliplatin/5-FU-based chemotherapy in advanced gastric cancer. J Korean Med Sci 25:846–852

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Inada M, Sato M, Morita S et al (2010) Associations between oxaliplatin-induced peripheral neuropathy and polymorphisms of the ERCC1 and GSTP1 genes. Int J Clin Pharmacol Ther 48:729–734

    Article  CAS  PubMed  Google Scholar 

  29. McLeod HL, Sargent DJ, Marsh S et al (2010) Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J Clin Oncol 28:3227–3233

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  30. Khrunin AV, Moisseev A, Gorbunova V, Limborska S (2010) Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J 10:54–61

    Article  CAS  PubMed  Google Scholar 

  31. Gamelin L, Capitain O, Morel A et al (2007) Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcome pathway. Clin Cancer Res 13:6359–6368

    Article  CAS  PubMed  Google Scholar 

  32. Keam B, Im SA, Han SW et al (2008) Modified FOLFOX-6 chemotherapy in advanced gastric cancer: results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker. BMC Cancer 8:148

    Article  PubMed Central  PubMed  Google Scholar 

  33. Paré L, Marcuello E, Altes A et al (2008) Pharmacogenetic prediction of clinical outcome in advanced colorectal cancer patients receiving oxaliplatin/5-fluorouracil as first-line chemotherapy. Br J Cancer 99:1050–1055

    Article  PubMed Central  PubMed  Google Scholar 

  34. Seo BG, Kwon HC, Oh SY et al (2009) Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI. Oncol Rep 22:127–136

    CAS  PubMed  Google Scholar 

  35. Boige V, Mendiboure J, Pignon JP et al (2010) Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J Clin Oncol 28:2556–2564

    Article  CAS  PubMed  Google Scholar 

  36. Kanai M, Yoshioka A, Tanaka S et al (2010) Associations between glutathione S-transferase π Ile105Val and glyoxylate aminotransferase Pro11Leu and Ile340Met polymorphisms and early-onset oxaliplatin-induced neuropathy. Cancer Epidemiol 34:189–193

    Article  CAS  PubMed  Google Scholar 

  37. Oguri T, Mitsuma A, Inada-Inoue M et al (2013) Genetic polymorphisms associated with oxaliplatin-induced peripheral neurotoxicity in Japanese patients with colorectal cancer. Int J Clin Pharmacol Ther 51:475–481

    Article  CAS  PubMed  Google Scholar 

  38. Won HH, Lee J, Park JO et al (2012) Polymorphic markers associated with severe oxaliplatin-induced, chronic peripheral neuropathy in colon cancer patients. Cancer 118: 2828–2836

    Article  CAS  PubMed  Google Scholar 

  39. Mir O, Alexandre J, Tran A et al (2009) Relationship between GSTP1 Ile(105)Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity. Ann Oncol 20:736–740

    Article  CAS  PubMed  Google Scholar 

  40. Booton R, Ward T, Heighway J et al (2006) Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer. J Thorac Oncol 1:679–683

    Article  PubMed  Google Scholar 

  41. Kim HS, Kim MK, Chung HH et al (2009) Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecol Oncol 113:264–269

    Article  CAS  PubMed  Google Scholar 

  42. Marsh S, Paul J, King CR et al (2007) Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish randomised trial in ovarian cancer. J Clin Oncol 25:4528–4535

    Article  CAS  PubMed  Google Scholar 

  43. Cho HJ, Eom HS, Kim HJ et al (2010) Glutathione-S-transferase genotypes influence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B-cell lymphoma. Cancer Genet Cytogenet 198:40–46

    Article  CAS  PubMed  Google Scholar 

  44. Baldwin RM, Owzar K, Zembutsu H et al (2012) A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res 18:5099–5109

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  45. Delague V, Jacquier A, Hamadouche T et al (2007) Mutations in fgd4 encoding the rho gdp/gtp exchange factor frabin cause autosomal recessive charcot-marie-tooth type 4 h. Am J Hum Genet 81:1–16

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  46. Stendel C, Roos A, Deconinck T et al (2007) Peripheral nerve demyelination caused by a mutant rho gtpase guanine nucleotide exchange factor, frabin/fgd4. Am J Hum Genet 81:158–164

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  47. Fabrizi GM, Taioli F, Cavallaro T et al (2009) Further evidence that mutations in fgd4/frabin cause charcotmarie-tooth disease type 4 h. Neurology 72:1160–1164

    Article  CAS  PubMed  Google Scholar 

  48. Houlden H, Hammans S, Katifi H, Reilly MM (2009) A novel frabin (fgd4) nonsense mutation p.R275x associated with phenotypic variability in cmt4h. Neurology 72:617–620

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  49. Lee JJ, Swain SM (2006) Peripheral neuropathy induced by microtubule stabilizing agents. J Clin Oncol 24:1633–1642

    Article  CAS  PubMed  Google Scholar 

  50. Cavaletti G, Cornblath DR, Merkies IS, The CI-PeriNomS Group et al (2013) The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol 24:454–462

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  51. Trotti A, Colevas AD, Setser A et al (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176–181

    Article  PubMed  Google Scholar 

  52. Merkies IS, Schmitz PI, van der Meche FG, Inflammatory Neuropathy Cause and Treatment (INCAT) Group et al (2000) Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Neurology 54:943–949

    Article  CAS  PubMed  Google Scholar 

  53. Cavaletti G, Frigeni B, Lanzani F et al (2007) The total neuropathy score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale. J Peripher Nerv Syst 12:210–215

    Article  PubMed  Google Scholar 

  54. Argyriou AA, Cavaletti G, Antonacopoulou A et al (2013) Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity – results from a prospective multicenter study. Cancer 119:3570–3577

    CAS  PubMed  Google Scholar 

  55. Antonacopoulou AG, Argyriou AA, Scopa CD et al (2010) Integrin beta-3 L33P: a new insight into the pathogenesis of chronic oxaliplatin-induced peripheral neuropathy? Eur J Neurol 17:963–968

    Article  CAS  PubMed  Google Scholar 

  56. Basso M, Modoni A, Spada D et al (2011) Polymorphism of CAG motif of SK3 gene is associated with acute oxaliplatin neurotoxicity. Cancer Chemother Pharmacol 67:1179–1187

    Article  CAS  PubMed  Google Scholar 

  57. Bergmann TK, Green H, Brasch-Andersen C et al (2011) Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. Eur J Clin Pharmacol 67:693–700

    Article  CAS  PubMed  Google Scholar 

  58. Broyl A, Corthals SL, Jongen JL et al (2010) Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol 11:1057–1065

    Article  CAS  PubMed  Google Scholar 

  59. Caponigro F, Lacombe D, Twelves C et al (2009) An EORTC phase I study of bortezomib in combination with oxaliplatin, leucovorin and 5-fl uorouracil in patients with advanced colorectal cancer. Eur J Cancer 45:48–55

    Article  CAS  PubMed  Google Scholar 

  60. Chang H, Rha SY, Jeung HC et al (2009) Association of the ABCB1 gene polymorphisms 2677G > T/A and 3435C > T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann Oncol 20:272–277

    Article  CAS  PubMed  Google Scholar 

  61. Chen YC, Tzeng CH, Chen PM et al (2010) Influence of GSTP1 I105V polymorphism on cumulative neuropathy and outcome of FOLFOX-4 treatment in Asian patients with colorectal carcinoma. Cancer Sci 101: 530–535

    Article  CAS  PubMed  Google Scholar 

  62. Favis R, Sun Y, van de Velde H et al (2011) Genetic variation associated with bortezomib-induced peripheral neuropathy. Pharmacogenet Genomics 21:121–129

    Article  CAS  PubMed  Google Scholar 

  63. Green H, Soderkvist P, Rosenberg P et al (2009) Pharmacogenetic studies of paclitaxel in the treatment of ovarian cancer. Basic Clin Pharmacol Toxicol 104:130–137

    Article  CAS  PubMed  Google Scholar 

  64. Hertz DL, Motsinger-Reif AA, Drobish A et al (2012) CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res Treat 134: 401–410

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  65. Isla D, Sarries C, Rosell R et al (2004) Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 15: 1194–11203

    Article  CAS  PubMed  Google Scholar 

  66. Johnson DC, Corthals SL, Walker BA et al (2011) Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol 29: 797–804

    Article  CAS  PubMed  Google Scholar 

  67. Leandro-Garcia LJ, Inglada-Pérez L, Pita G et al (2013) Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathy. J Med Genet 50:599–605

    Article  CAS  PubMed  Google Scholar 

  68. Leskela S, Jara C, Leandro-Garcia LJ et al (2011) Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity. Pharmacogenomics J 11: 121–129

    Article  CAS  PubMed  Google Scholar 

  69. Rizzo R, Spaggiari F, Indelli M et al (2010) Association of CYP1B1 with hypersensitivity induced by taxane therapy in breast cancer patients. Breast Cancer Res Treat 124: 593–598

    Article  CAS  PubMed  Google Scholar 

  70. Sissung TM, Mross K, Steinberg SM et al (2006) Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. Eur J Cancer 42:2893–2896

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  71. Sissung TM, Baum CE, Deeken J et al (2008) ABCB1 genetic variation influences the toxicity and clinical outcome of patients with androgen-independent prostate cancer treated with docetaxel. Clin Cancer Res 14:4543–4549

    Article  CAS  PubMed Central  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery and Translational Medicine, University of Milano-Bicocca, Cadore 48, Monza, 20900, Italy

    Paola Alberti & G. Cavaletti

Authors
  1. Paola Alberti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. Cavaletti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paola Alberti .

Editor information

Editors and Affiliations

  1. PharmTao, Santa Clara, California, USA

    Qing Yan

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this protocol

Cite this protocol

Alberti, P., Cavaletti, G. (2014). Management of Side Effects in the Personalized Medicine Era: Chemotherapy-Induced Peripheral Neuropathy. In: Yan, Q. (eds) Pharmacogenomics in Drug Discovery and Development. Methods in Molecular Biology, vol 1175. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-0956-8_12

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-0956-8_12

  • Published:

  • Publisher Name: Humana Press, New York, NY

  • Print ISBN: 978-1-4939-0955-1

  • Online ISBN: 978-1-4939-0956-8

  • eBook Packages: Springer Protocols

Publish with us

Policies and ethics

Search

Navigation